EMERALD Trial: Elacestrant for ER+/HER2- Metastatic Breast Cancer

The FDA has granted breakthrough therapy designation to the DCISionRT test, a tool that assesses radiation therapy benefit for women aged 30 to 85 with ductal carcinoma in situ.

In this episode of Targeted Talks, Sanjay K. Juneja, MD, discusses the exciting advancements of artificial intelligence in 2024.

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic breast cancer who had progressed on multiple line of therapy.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed how the outcomes of the DESTINY-Breast03 and other trials impact treatment of metastatic HER2-positive breast cancer in the second article of a 2-part series.

The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as supported by new phase 1 data.